Instrument Inactif

Communiqués Össur hf. Other OTC

Actions

Embla Medical hf: Interim Report Q1 2024	23/04	AQ
Össur hf: Board Decisions Following the Annual General Meeting	13/03	AQ
Össur hf: Results of the Annual General Meeting	13/03	AQ
Össur hf: Candidates to the Board of Directors	10/03	AQ
Össur hf: Final Agenda and Proposals for the Annual General Meeting 13 March 2024	28/02	AQ
Össur hf: Össur establishes new parent organization to be named Embla Medical	21/02	AQ
Össur hf: Annual General Meeting 13 March 2024	21/02	AQ
Össur hf: Annual Report 2023	30/01	AQ
Össur hf: Interim Report Q4 2023	30/01	AQ
Össur hf: Össur's total share capital following completion of capital increase of 6,636,122 shares	24/01	AQ
Össur hf: Össur acquires FIOR & GENTZ	16/01	AQ
Össur hf: Financial Calendar 2024	20/12	AQ
Össur hf: Major Shareholder Announcement	21/11	AQ
Össur hf: Interim report Q3 2023	24/10/23	AQ
Ukrainian medical professionals receive comprehensive training in the field of lower limb prosthetics	16/10/23	AQ
Össur : Össur R&D insights shared with leading inventors and innovators	14/09/23	PU
Össur : Scottish Enterprise provides R&D funding grant to Össur to develop upper limb prosthetics	06/09/23	PU
Össur hf: Interim Report Q2 2023	25/07/23	AQ
Össur Salutes Team Össur members' Exceptional Performance at 2023 World Para Athletics Championships in Paris	20/07/23	AQ
Össur hf: Össur Appoints Lukas Märklin as Chief Operating Officer	15/06/23	AQ

Aucun résultat pour cette recherche